BetterLife Pharma Inc. BETR
CNSX
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 101.73% | 44.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 105.64% | 29.92% | |||
| Operating Income | -105.64% | -29.92% | |||
| Income Before Tax | -235.24% | -62.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -235.24% | -62.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 96.00% | 212.50% | |||
| Net Income | -236.03% | -61.95% | |||
| EBIT | -105.64% | -29.92% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -217.24% | -61.11% | |||
| Normalized Basic EPS | -200.00% | -58.33% | |||
| EPS Diluted | -220.69% | -61.11% | |||
| Normalized Diluted EPS | -200.00% | -58.33% | |||
| Average Basic Shares Outstanding | 5.11% | 1.93% | |||
| Average Diluted Shares Outstanding | 5.11% | 1.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||